A Double-blind, Randomized, Placebo-controlled, Pharmacokinetic, Safety, and Tolerability Study of CSL112 in Adult Subjects With Moderate Renal Impairment and in Healthy Adult Subjects With Normal Renal Function

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Pharmacokinetic, Safety, and Tolerability Study of CSL112 in Adult Subjects With Moderate Renal Impairment and in Healthy Adult Subjects With Normal Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs CSL 112 (Primary)
  • Indications Myocardial infarction
  • Focus Pharmacokinetics
  • Sponsors CSL Behring
  • Most Recent Events

    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 16 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 17 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top